IDEAYA Biosciences (IDYA) News Today → The only financial event in 2024 that matters (From Porter & Company) (Ad) Free IDYA Stock Alerts $36.55 +0.76 (+2.12%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 1:32 AM | americanbankingnews.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $46.80 Consensus PT from AnalystsJune 1 at 8:53 AM | insidertrades.comInsider Selling: IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Insider Sells 28,500 Shares of StockMay 31 at 4:43 PM | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Insider Michael Anthony White Sells 28,500 SharesIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) insider Michael Anthony White sold 28,500 shares of IDEAYA Biosciences stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $36.24, for a total value of $1,032,840.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.May 31 at 6:00 AM | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 30 at 9:55 PM | marketbeat.com55,239 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Capstone Investment Advisors LLCCapstone Investment Advisors LLC acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 55,239 shares of the company's stock, valued at approximately $1,965,000. CapstMay 30 at 1:37 AM | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Buy" from AnalystsShares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have received an average rating of "Buy" from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. Twelve equities research analysts have rated the stock with a buy rating. The average 1 year priMay 29, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations EventsMay 28, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Down to $37.71IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Down to $37.71May 28, 2024 | finanznachrichten.deIDEAYA Biosciences, Inc.: IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business DevelopmentMay 28, 2024 | prnewswire.comIDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business DevelopmentMay 27, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Acquired by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 13.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 496,456 shares of the company'sMay 27, 2024 | americanbankingnews.comFY2028 EPS Estimates for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Cut by Capital One FinancialMay 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Mirum Pharmaceuticals (MIRM) and IDEAYA Biosciences (IDYA)May 24, 2024 | markets.businessinsider.comBuy Rating on IDEAYA Biosciences: Darovasertib’s Market Potential and Promising Clinical ResultsMay 23, 2024 | finance.yahoo.com/C O R R E C T I O N -- IDEAYA Biosciences, Inc./May 23, 2024 | prnewswire.comIDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal MelanomaMay 22, 2024 | marketbeat.comSwiss National Bank Lowers Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Swiss National Bank trimmed its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 20.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 85,100 shares of the company's stock after sellMay 21, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Stock Price Up 4.1%IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Up 4.1%May 19, 2024 | marketbeat.comBNP Paribas Financial Markets Purchases 155,179 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)BNP Paribas Financial Markets boosted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 295.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 207,735 shares of the company's stock after purchasingMay 17, 2024 | insidertrades.comInsider Selling: IDEAYA Biosciences, Inc. (NASDAQ:IDYA) CEO Sells 34,433 Shares of StockMay 16, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) CEO Sells $1,439,643.73 in StockIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) CEO Yujiro S. Hata sold 34,433 shares of the company's stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $41.81, for a total value of $1,439,643.73. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares of the company's stock, valued at approximately $28,342,455.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.May 16, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Short Interest UpdateIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totalling 10,680,000 shares, an increase of 8.6% from the April 15th total of 9,830,000 shares. Approximately 16.2% of the company's shares are short sold. Based on an average daily trading volume, of 701,700 shares, the days-to-cover ratio is presently 15.2 days.May 15, 2024 | marketbeat.comNicholas Investment Partners LP Invests $3.93 Million in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Nicholas Investment Partners LP purchased a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 110,351 shares of the company'sMay 13, 2024 | marketbeat.comThe Goldman Sachs Group Cuts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $46.00The Goldman Sachs Group decreased their price target on shares of IDEAYA Biosciences from $53.00 to $46.00 and set a "buy" rating on the stock in a research note on Monday.May 12, 2024 | marketbeat.comVictory Capital Management Inc. Takes Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Victory Capital Management Inc. acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 346,490 shares of the company's stock, valued at approximatelMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for IDEAYA Biosciences Amid Promising Clinical Updates and Pipeline CatalystsMay 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Decreased by Leerink PartnrsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Research analysts at Leerink Partnrs lowered their Q2 2024 earnings per share estimates for shares of IDEAYA Biosciences in a research report issued to clients and investors on Tuesday, May 7th. Leerink Partnrs analyst A. Berens now expects tMay 10, 2024 | marketbeat.comNew York State Common Retirement Fund Boosts Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)New York State Common Retirement Fund lifted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 98.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,657 shaMay 9, 2024 | marketbeat.comIDEAYA Biosciences, Inc. to Post Q1 2025 Earnings of ($0.72) Per Share, Wedbush Forecasts (NASDAQ:IDYA)IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Stock analysts at Wedbush issued their Q1 2025 earnings estimates for shares of IDEAYA Biosciences in a report issued on Tuesday, May 7th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.72) for thMay 8, 2024 | markets.businessinsider.comUnveiling 5 Analyst Insights On IDEAYA BiosciencesMay 8, 2024 | finance.yahoo.comIDEAYA Biosciences First Quarter 2024 Earnings: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)May 8, 2024 | marketbeat.comIDEAYA Biosciences' (IDYA) "Outperform" Rating Reiterated at WedbushWedbush reiterated an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday.May 8, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPSIDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 23.00%. The company's revenue was down 100.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.49) earnings per share.May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: IDEAYA Biosciences’ Promising Pipeline and Strong Financial PositionMay 7, 2024 | investorplace.comIDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024May 7, 2024 | finance.yahoo.comIDEAYA Biosciences Inc (IDYA) Reports Q1 2024 Earnings: Financial and Strategic DevelopmentsMay 7, 2024 | prnewswire.comIDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | marketbeat.comFisher Asset Management LLC Buys 507,500 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Fisher Asset Management LLC raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 1,609.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 539,025 shares of the compaMay 1, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations EventApril 26, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 24, 2024 | prnewswire.comIDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored StudyApril 22, 2024 | prnewswire.comIDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung CancerApril 18, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Trading Down 3.2%IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 3.2%April 18, 2024 | marketbeat.comFederated Hermes Inc. Boosts Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Federated Hermes Inc. increased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 14.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,883,775 shares of the company's stocApril 16, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Short Interest Up 6.7% in MarchIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 9,410,000 shares, an increase of 6.7% from the March 15th total of 8,820,000 shares. Currently, 14.3% of the company's stock are short sold. Based on an average daily volume of 905,000 shares, the short-interest ratio is currently 10.4 days.April 10, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of "Buy" by AnalystsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has received a consensus recommendation of "Buy" from the thirteen brokerages that are currently covering the company, Marketbeat.com reports. Thirteen analysts have rated the stock with a buy recommendation. The average 12 month price targeApril 6, 2024 | marketbeat.comVanguard Group Inc. Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Vanguard Group Inc. lifted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 5.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,971,497 shares of the company's stock after purchasing an additional 141,844 shares during the peApril 5, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations EventMarch 21, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $60.00 at CitigroupCitigroup boosted their target price on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday. Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.” Click here to find out who they are. IDYA Media Mentions By Week IDYA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IDYA News Sentiment▼0.380.75▲Average Medical News Sentiment IDYA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IDYA Articles This Week▼173▲IDYA Articles Average Week Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Catalyst Pharmaceuticals News Syros Pharmaceuticals News Cue Biopharma News Sarepta Therapeutics News Catalent News Roivant Sciences News Elanco Animal Health News Legend Biotech News Cerevel Therapeutics News Ascendis Pharma A/S News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IDYA) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.